EA200500957A1 - APPLICATION OF L-DOPA, ITS DERIVATIVES AND MEDICINES CONTAINING THESE COMPOUNDS FOR THE PREVENTION OF PSYCHOTICAL DISEASES - Google Patents

APPLICATION OF L-DOPA, ITS DERIVATIVES AND MEDICINES CONTAINING THESE COMPOUNDS FOR THE PREVENTION OF PSYCHOTICAL DISEASES

Info

Publication number
EA200500957A1
EA200500957A1 EA200500957A EA200500957A EA200500957A1 EA 200500957 A1 EA200500957 A1 EA 200500957A1 EA 200500957 A EA200500957 A EA 200500957A EA 200500957 A EA200500957 A EA 200500957A EA 200500957 A1 EA200500957 A1 EA 200500957A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
diseases
dopa
derivatives
impaired
Prior art date
Application number
EA200500957A
Other languages
Russian (ru)
Inventor
Рудольф-Гизберт Алкен
Original Assignee
Бдд Беролина Драг Девелопмент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бдд Беролина Драг Девелопмент Гмбх filed Critical Бдд Беролина Драг Девелопмент Гмбх
Publication of EA200500957A1 publication Critical patent/EA200500957A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Предложенное изобретение относится к применению L-допа, его производных или их физиологически переносимых солей для профилактики психотических заболеваний и для лечения заболеваний, вызванных нарушением передачи тирозина или нарушенной тирозиндекарбоксилазой. Кроме того изобретение относится к фармацевтическим составам, содержащим L-допа, его производные или физиологически переносимые соли для профилактики психотических заболеваний, вместе с фармацевтически совместимыми вспомогательными веществами и добавками. Кроме этого изобретение относится к композициям, состоящим из L-допа, его производных или их физиологически переносимых солей и ферментных угнетателей активности, для профилактики психотических заболеваний и для лечения заболеваний, вызванных нарушением передачи тирозина или нарушенной тирозиндекарбоксилазой, а также к соответствующим фармацевтическим составам для профилактики психотических заболеваний и для лечения заболеваний, вызванных нарушением передачи тирозина или нарушенной тирозиндекарбоксилазой.Отчет о международном поиске был опубликован 2004.11.11.The proposed invention relates to the use of L-dopa, its derivatives or their physiologically tolerable salts for the prevention of psychotic diseases and for the treatment of diseases caused by impaired transmission of tyrosine or impaired tyrosine decarboxylase. In addition, the invention relates to pharmaceutical compositions containing L-dopa, its derivatives or physiologically tolerable salts for the prevention of psychotic diseases, together with pharmaceutically compatible excipients and additives. In addition, the invention relates to compositions consisting of L-dopa, its derivatives or their physiologically tolerable salts and enzyme inhibitors of activity for the prevention of psychotic diseases and for the treatment of diseases caused by impaired tyrosine transmission or impaired tyrosine decarboxylase, as well as to appropriate pharmaceutical compositions for the prevention psychotic diseases and for the treatment of diseases caused by impaired tyrosine transmission or impaired tyrosine decarboxylase. A report on international the lawsuit was published 2004.11.11.

EA200500957A 2002-12-19 2003-12-18 APPLICATION OF L-DOPA, ITS DERIVATIVES AND MEDICINES CONTAINING THESE COMPOUNDS FOR THE PREVENTION OF PSYCHOTICAL DISEASES EA200500957A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10261808A DE10261808A1 (en) 2002-12-19 2002-12-19 Use of L-DOPA, its derivatives and medicaments containing these compounds for the prophylaxis of psychotic diseases
PCT/DE2003/004204 WO2004056306A2 (en) 2002-12-19 2003-12-18 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases

Publications (1)

Publication Number Publication Date
EA200500957A1 true EA200500957A1 (en) 2006-02-24

Family

ID=32478131

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500957A EA200500957A1 (en) 2002-12-19 2003-12-18 APPLICATION OF L-DOPA, ITS DERIVATIVES AND MEDICINES CONTAINING THESE COMPOUNDS FOR THE PREVENTION OF PSYCHOTICAL DISEASES

Country Status (10)

Country Link
EP (1) EP1615631A2 (en)
JP (1) JP2006511558A (en)
CN (1) CN1756542A (en)
AU (1) AU2003294664A1 (en)
CA (1) CA2513077A1 (en)
DE (1) DE10261808A1 (en)
EA (1) EA200500957A1 (en)
MX (1) MXPA05006409A (en)
PL (1) PL377524A1 (en)
WO (1) WO2004056306A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401842D0 (en) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
UA97795C2 (en) * 2006-02-17 2012-03-26 Бьордз Фарма Гмбх Бероліна Інновейтів Ресерч Унд Девелопмент Сервісіз Deuterated catecholamine derivatives and medicaments comprising said compounds
CN105078952A (en) * 2015-08-10 2015-11-25 中国康复研究中心 Levodopa preparation and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) * 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder
IE47082B1 (en) * 1977-07-01 1983-12-14 Merrell Toraude & Co -acetylenic amino acids
US5149786A (en) * 1989-10-12 1992-09-22 Chiron Corporation Dopamine releasing protein and antibody

Also Published As

Publication number Publication date
WO2004056306A2 (en) 2004-07-08
CN1756542A (en) 2006-04-05
DE10261808A1 (en) 2004-07-08
MXPA05006409A (en) 2006-05-31
AU2003294664A1 (en) 2004-07-14
CA2513077A1 (en) 2004-07-08
JP2006511558A (en) 2006-04-06
EP1615631A2 (en) 2006-01-18
PL377524A1 (en) 2006-02-06
WO2004056306A3 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
EA200801826A1 (en) DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICINES CONTAINING INDICATED COMPOUNDS
EA200201271A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
DK1317419T3 (en) Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
EA200801492A1 (en) PHARMACEUTICAL APPLICATION OF SUBSTITUTED AMIDES
NO20025601D0 (en) Arylmethylamine derivatives for use as tryptase inhibitors
NO20050851L (en) Caspase Inhibitors and Uses thereof
EA200300776A1 (en) FENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
EA200702498A1 (en) N- (PYRIDIN-2-IL) SULPHONAMIDE DERIVATIVES
EA200800880A1 (en) COMBINATION OF ROSIGLITAZONE AND DROPSEEN, INTENDED TO IMPROVE COGNITIVE FUNCTION
NO20022442L (en) Medicines for diseases related to reduction in bone mass
RU2008127882A (en) TREATMENT OF THE ESOPHAGUS OF BARRETT
BRPI0410727A (en) compound, pharmaceutical composition, and use of a compound
EA200401227A1 (en) DELIVERY DELIVERY SYSTEM WITH CONTROLLED DELAY, INCLUDING PRAVASTATIN
EA200401515A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN IN POLYMORPHIC MODIFICATION A
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
EA200501821A1 (en) PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION
SE0102440D0 (en) New compound
EA200400707A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
ATE410152T1 (en) THERAPEUTIC SYSTEM WITH AMOXICILLIN AND CLAVULANIC ACID
MXPA05008403A (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms.
EA200500957A1 (en) APPLICATION OF L-DOPA, ITS DERIVATIVES AND MEDICINES CONTAINING THESE COMPOUNDS FOR THE PREVENTION OF PSYCHOTICAL DISEASES
NO20052562L (en) Use of distrontium salts of 2- [N, N-di (carboxylmethyl) amino] -3-cyano-4-carboxylmethyl-thiophene-5-carboxylic acid for the preparation of medicaments for the treatment of gastro-duodenal pain.
SE0000303D0 (en) Novel compounds
MXPA05008711A (en) Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain.